Stay updated with the most recent articles and resources.
June 2016: Professor Huang He of Zhejiang University’s First Affiliated Hospital presented the outcomes of 10 clinical cases, including CAR-T cell therapy for leukaemia treatment, at...
Feb 2022: A 12-year-old girl from southwest China’s Chongqing Municipality was saved by an unconventional therapy instead of chemotherapy or hematopoietic stem cell transplantation. Yi...
4th Feb 2022: In India, cancer can have serious social and economic effects, typically resulting in family destitution and societal injustice. In this demographically young...
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, has been licenced by the Food and Drug Administration for adult patients with ovarian...
Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug Administration licenced sirolimus protein-bound particles for...
Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who...
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug....
Nov 2021: Asciminib (Scemblix, Novartis AG) was given accelerated approval by the Food and Drug Administration for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+...
Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell...
Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration for patients with...
October 2021: The Food and Drug Administration has approved abemaciclib (Verzenio, Eli Lilly and Company) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor)...
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell...
We wish a speedy recovery for your loved ones.